Childhood Cancer Program
Some childhood cancers have either no treatment available, or what is available hasn’t improved for more than forty years.
These rare, low-survival, difficult-to-treat childhood cancers are among the specialities of Hudson Institute researchers.
Each year almost 1,000 Australian children are diagnosed with childhood cancer and 5,600 are undergoing treatment.
Despite significant improvements in overall survival rates over the past 50 years, cancer remains the leading disease-related cause of death among Australian children.
The pharmaceutical industry’s limited focus on developing new treatments for paediatric cancers stems from their comparatively low incidence relative to adult cancers.
Some rare childhood cancers have no treatments available. In the last 40 years, 500 adult cancer drugs were approved in the United States, contrasting with only 12 for childhood cancers. The development of more targeted and less toxic treatments for children with cancer is imperative to improve survival rates and reduce long-term treatment-related side effects.
Our Childhood Cancer Research Programs aim to improve survival rates and long-term health outcomes for children with cancer by mitigating the detrimental effects of aggressive treatments on their developing bodies.
Leadership and goals
A world leader in the field of paediatric cancer research, Hudson Institute’s multidisciplinary team of researchers and clinicians have the following primary objectives
- Developing more precise treatments to improve childhood cancer long-term prognosis, survival rates, and long-term health outcomes.
- Fostering local, national, and international partnerships to build capacity and sustainability in paediatric cancer research.
- Advancing the understanding of cancer biology through cutting-edge research, focusing on the unique genetic and molecular profiles of paediatric cancers.
- Translating research into clinical practice by facilitating the implementation of research findings into clinical trials for paediatric cancer patients.
- Engaging in advocacy and education to raise awareness about the unique challenges of paediatric cancer and to secure funding and policy support for ongoing research and treatment initiatives.
In Australia, more than 1,000 children and adolescents are diagnosed with cancer each year.
Cancer kills three children every week in Australia – more than any other disease.
Almost half of all children diagnosed with cancer in Australia are aged 0-4 years old.
Next Generation Precision Medicine Program
The Next Generation Precision Medicine Program aims to significantly improve the treatment, survival and quality of life for children with cancer, with a special focus on brain cancer.
Learn more
AYA Sarcoma Program
Our sarcoma program includes both clinical and discovery research projects utilizing a broad range of patient tissue, in vitro and in vivo preclinical models, and techniques.
Learn more
Immunotherapy Program
Childhood cancer poses a significant scientific and medical challenge, and within this field, immunotherapy and cancer vaccines emerge as promising, less toxic treatment options.
Learn more
Acute Myeloid Leukemia Program
Our childhood AML program aims to identify critical mechanism underpinning AML development, relapse and therapy resistance.
Learn more
Advanced Informatics program
The Advanced Informatics program develops and applies state-of-the-art computational approaches to rapidly screen samples of the most challenging paediatric cancers against thousands of genetic alterations for potential therapeutic vulnerabilities.
Learn more
Childhood Cancer Model Atlas
The Childhood Cancer Model Atlas (CCMA), housed at Hudson Institute’s Centre for Cancer Research, is the world’s largest collection of over 400 high-risk paediatric cancer cell lines. This unique and open-source repository was established through the collaboration of more than 50 leading cancer research institutes, universities, and academic medical centres worldwide.
Hudson-Monash Children Cancer Biobank and Living Biobank
The Hudson-Monash Children’s Cancer Biobank (MCCB) was established in 2011 and is operated by the Hudson Institute’s Centre for Cancer Research. Since 2017, the biobank has expanded to include a Living Biobank, a cutting-edge resource that features patient ‘avatar’ models. These models faithfully replicate the patient’s original tumour and include cell lines, organoids, and patient-derived xenografts (PDXs).
Publication highlights
2024
2023
2022
2021
2020
2019
2017
2016
2014
2013
2012
Program leads
Professor Ron Firestein, Centre Head, Centre for Cancer Research, Lead Next generation precision medicine program
Associate Professor Jason Cain, Research Group Head Sarcoma program
Dr Pouya Faridi, Research Group Head Cancer immunotherapy program
Dr Catherine Carmichael, Research Group Head Childhood myeloid leukemia program
Dr Xin (Claire) Sun, Advanced informatics program
Program operations
Naama Neeman, Head of Program Operations
Laboratory operations
Gilu Abraham, Laboratory Manager
Hui Kheng Chua, Laboratory Manager
Research team
Dr Paul Daniel, Senior Postdoctoral Research Fellow
Dr Terry Lim, Postdoctoral Scientist
Dr Hanbyeol Lee, Postdoctoral Scientist, Paediatric Brain Cancer
Dr Yichen Zhou, Postdoctoral Scientist, Combinatorial CRISPR Technology
Dr Farnaz Fahimi, Postdoctoral Scientist
Dr Gabriel Goncalves, Postdoctoral Scientist
Shazia Adjumain, Postdoctoral Scientist, Functional Genomics – funded by Robert Connor Dawes Foundation
Dr Danxi Zhu, Postdoctoral Scientist
Dr Ava Faridi, Grant and manuscript writering
Yuxin (Sally) Sun, Cooper Rice-Brading Foundation – Sarcoma Research Specialist
Dr Steve Lin, Research Assistant
Nivedhitha Selvakumar, Research Assistant
Jennie Do, Research Assistant
Samiksha Dhananjay, Research Assistant – volunteer
Jin Luo, Research Assistant – volunteer
Biobanking and cell culture specialists
Rajithri (Dilru) Habarakada, Senior Biobank Specialist
Dr Nicole Chew, Senior Organoid Specialist
Bao Le, Research Assistant, Junior Organoid Specialist
James Cooper, Research Assistant, Patient Model Specialist
Bioinformatics researchers
Isaac Woodhouse, Senior Bioinformatician
Vincent Xue, Bioinformatician
Vikesh Ajith, Bioinformatics Data Engineer
Xinyi Guo, Research Assistant
Rafia Ahmed, Vacation student
Ishika Mahajan, Volunteer
Yiwen Guan, Volunteer
Clinical staff
Dr Lakshmi (Priya) Sundaravel, Paediatric Fellow, The Royal Children’s Hospital
Dr Leanne Super, Paediatric Oncologist, The Royal Children’s Hospital and Monash Children’s Hospital
Students
Liesl Bramberger, PhD Student
Dr Yuqing Liang, Children’s Cancer Foundation PhD Student
Dr Tima Shamekhi, PhD Student
Erwin Tanuwidjaya, PhD Student
Grace Huang, PhD Student
Dr Nataliya Zhukova, PhD Student
Dingyin Sun, PhD Student
Dr Elise Young, PhD Student
Barnaby Kelly, PhD Student
Lynda Truong, PhD Student
Nurfarhanah (Farhanah) Syed Sulaiman, PhD Scholar
Samitha Amarapathy, PhD student, Faculty of IT, Monash University
Anqelique (Angie) Bitticaca, Honours Student
Karyn Tjahyadi, Visiting Student
The Childhood Cancer Program is conducted in collaboration with more than 50 leading cancer research institutes, universities, and academic medical centres worldwide.
National
- Centre for Cancer Biology, SA
- Flinders University, SA
- Monash Children’s Hospital, VIC
- Monash University, VIC
- Murdoch Children’s Research Institute, VIC
- Peter MacCallum Cancer Centre, VIC
- QIMR Berghofer Medical Research Institute, QLD
- Queensland Children’s Tumour Bank, QLD
- The Alfred, VIC
- The Kids Research Institute Australia, WA
- The Royal Children’s Hospital Melbourne, VIC
- The Royal Melbourne Hospital, VIC
- The Sydney Children’s Hospitals Network, NSW
- The University of Melbourne, VIC
- The University of Queensland, QLD
- The Walter and Eliza Hall Institute, VIC
- University of Newcastle, NSW
- Zero Childhood Cancer, NSW
- Children’s Medical Research Institute, NSW
- Hunter Medical Research Centre, NSW
- St. Vincent’s Hospital Melbourne, VIC
International
- American Type Culture Collection (ATCC), United States
- Bambino Gesù Children’s Hospital, Italy
- Boston Children’s Hospital, United States
- Chidren’s Hospital of Philadelphia, United States
- Childhood Cancer Repository, United States
- Children’s Brain Tumour Network (CBTN), United States
- Children’s Hospital Los Angeles, United States
- Children’s Hospital Zurich, Switzerland
- Children’s National Hospital, United States
- Chordoma Foundation, United States
- Dana-Farber Cancer Institute, United States
- Dayton Children’s, United States
- Duke University, United States
- Fred Hutchinson Cancer Center, United States
- German Cancer Research Center (DKFZ), Germany
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Germany
- Johns Hopkins University, United States
- KK Women’s and Children’s Hospital, Singapore
- Leibniz Institute DSMZ, Germany
- Life Technologies, United States
- McGill University, Canada
- Merck, United States
- NIBIOHN Japanese Collection of Research Bioresources (JCRB) Cell Bank, Japan
- Princess Máxima Center for Pediatric Oncology, Netherlands
- Sant Joan de Déu Barcelona Children’s Hospital, Spain
- Spanish National Cancer Research Center (CNIO), Spain
- St. Jude Children’s Research Hospital, United States
- Stanford University, United States
- The Hospital for Sick Children (SickKids), Canada
- The Institute of Cancer Research, UK
- University of Calgary, Canada
- University of California San Francisco, United States
- University of Cambridge, UK
- University of Colorado, United States
- University of Lübeck, Germany
- University of Michigan, United States
- VU University Medical Center, Netherlands
The Childhood Cancer Program acknowledges the support of
Funders
- Australian Communities Foundation
- Australian Lions Childhood Cancer Research Foundation
- Cancer Australia
- Children’s Cancer Foundation
- Cooper Rice-Brading Foundation
- Isabella and Marcus Foundation
- Medical Research Future Fund
- Monash Partners Comprehensive Cancer Consortium
- My Room
- Robert Connor Dawes Foundation
- Run DIPG
- The Kids’ Cancer Project
- Tour de Cure
- Victoria State Government
- Victorian Cancer Agency
Patient and family advisors play a crucial role in shaping our childhood cancer research program by bringing invaluable insights from their personal experiences with childhood cancer.
Our advisors include caregivers of children who are currently undergoing treatment, caregivers of those who have passed away from childhood cancer and survivors of childhood cancer (or their carers). These individuals provide vital recommendations that guide our research efforts, ensuring that the perspectives of patients and families are incorporated into every stage of planning, delivery, and evaluation. They also offer advice on how to effectively communicate our research outcomes to the broader community. This collaborative approach enhances our mission of fostering partnerships, developing precise treatments, and improving both survival rates and long-term health outcomes for childhood cancer patients.
Courtney Baglin
Childhood and AYA Sarcoma program
Immunotherapy program
Next generation precision medicine
Monique Boggia
Next generation precision medicine
Andrea Boon
Leukaemia program
Prof Tracey Danaher
Next generation precision medicine
Advanced informatics program
Nader Eloshaiker
Leukaemia program
Lucy Francazio
Leukaemia program
Dr Rebecca Goldstein
Next generation precision medicine
Advanced informatics program
Claire Josefsson
Leukaemia program
Advanced informatics program
Leesa Kerr
Childhood and AYA Sarcoma program
Immunotherapy program
Next generation precision medicine
Taylah Miranda
Leukaemia program
Nelly Mohibi
Childhood and AYA Sarcoma program
Immunotherapy program
Next generation precision medicine
Virginia Rea
Next generation precision medicine
Jen Rooney
Next generation precision medicine
Advanced informatics program
Dr Lori Rubinek
Next generation precision medicine
Andrea Valvo
Leukaemia program
Tianna Valvo
Leukaemia program
Anita Watts
Childhood and AYA Sarcoma program
Immunotherapy program
Next generation precision medicine